Biopsies of castration resistant prostate cancer metastases were subjected to whole genome sequencing (WGS), along with RNA-sequencing (RNA-Seq). The overarching goal of the study is to illuminate molecular mechanisms of acquired resistance to therapeutic agents, and particularly androgen signaling inhibitors, in the treatment of metastatic castration resistant prostate cancer (mCRPC). This study is made available on AWS via the NIH STRIDES Initiative.
Genomic Data Commons (GDC) is source of truth for this dataset; GDC offers monthly data releases, although this dataset may not be updated at every release.
NIH Genomic Data Sharing Policy: https://gdc.cancer.gov/access-data/data-access-policies
See all datasets managed by Center for Translational Data Science at The University of Chicago.
Genomic Characterization of Metastatic Castration Resistant Prostate Cancer was accessed on
DATE from https://registry.opendata.aws/mcrpc. dbGaP accession phs001648.v2.p1
aws s3 ls --no-sign-request s3://gdc-wcdt-mcrpc-phs001648-2-open/